One-glance verdict
Not enough data
Fair value unavailable
Not enough cash-flow history to value this one with our method.
Fundamentals snapshot
Marker Therapeutics, Inc.
MRKR · NCM · Healthcare · Biotechnology
Current price
$1.01
52-week range
$0.84 - $2.46
Market cap
$16.84M
Balance sheet
Healthy
-20.93x Concerning
Net cash $11.33M. Interest coverage shows how many times profit covers the interest bill.
What stands out
0 Rewards
2 Risks
0 rewards · 2 risks
- Risk Return on equity was -76.9% last year — the company lost money on shareholders' equity.
- Risk Insider ownership is only 5.5% (peer median: 8.8%).
What this company does
Marker Therapeutics, Inc.
Marker Therapeutics is developing a type of cancer treatment that uses a patient's own immune cells to fight tumors. Their main focus is on creating these new therapies, which is why their money mostly comes from research and development activities, not from selling products yet. This matters because it shows they are investing heavily in future treatments, which could be very valuable if successful.
How the company got here
Marker Therapeutics, Inc. was founded in 1999 and was formerly known as TapImmune, Inc. before changing its name in October 2018. The company is a clinical-stage immuno-oncology firm focused on developing T cell-based therapies for cancer. Its technology, developed at Baylor College of Medicine, aims to harness the body's own immune system to fight cancer. Marker Therapeutics has undergone various stages of development, including mergers and acquisitions, to advance its pipeline of innovative treatments. The company has a history of seeking funding to support its research and clinical trials, with a focus on developing novel treatments for challenging diseases.
What it actually does
Marker Therapeutics develops T cell-based immunotherapies, which are treatments that use a patient's own immune cells to fight cancer. Their main technology, called Multi-Antigen Recognizing (MAR)-T cell therapy, involves selecting and expanding specific T cells from a patient's blood that can identify and attack cancer cells. Unlike some other T cell therapies that require genetic engineering, Marker's approach uses naturally occurring T cells, which they believe leads to simpler manufacturing and potentially fewer side effects. The company is focused on developing these therapies for both blood cancers (hematological malignancies) and solid tumors.
Multi-Antigen Recognizing (MAR)-T cell Therapies
This is Marker Therapeutics' core business. They are developing therapies that use a patient's T cells (a type of immune cell) to fight cancer. Their unique approach, MAR-T cell therapy, focuses on T cells that can recognize multiple targets (antigens) on cancer cells. This is important because cancer cells can change, and by targeting multiple antigens, the therapy is less likely to be evaded by the cancer. Marker's lead product candidate, MT-601, is currently in Phase 1 clinical trials for lymphoma patients who have not responded to other treatments. They also have another product candidate, MT-401-OTS, in Phase 1 trials for acute myeloid leukemia and myelodysplastic syndromes. These therapies are still in the testing phase (clinical trials) and are not yet approved for widespread use.
What management is betting on now
Marker Therapeutics is strategically prioritizing its development efforts on its Multi-Antigen Recognizing (MAR)-T cell therapies, particularly focusing on MT-601 for lymphoma patients who have relapsed after or are ineligible for other treatments. Management believes this focus addresses a significant unmet medical need. They are also exploring 'off-the-shelf' (OTS) versions of their therapies, which could allow for faster treatment initiation compared to personalized cell therapies. The company is also working to enhance its manufacturing capabilities to support the advancement of its product candidates through clinical trials and towards potential commercialization.
Price history
How the share price has moved
—
Loading price history…
Earnings history
Last 8 quarters — what happened
Click any quarter to read the call summary and what the numbers say.
Revenue
—
Net income
$-1.83M
Diluted EPS
-0.09
Operating cash flow
$-3.72M
Free cash flow
—
Fetching…
Sources
Revenue
—
Net income
$-3.18M
Diluted EPS
-0.16
Operating cash flow
$-1.40M
Free cash flow
—
Fetching…
Sources
Revenue
—
Net income
$-1.70M
Diluted EPS
0.02
Operating cash flow
$-1.90M
Free cash flow
—
Fetching…
Sources
Revenue
—
Net income
$-2.00M
Diluted EPS
-0.12
Operating cash flow
$-2.74M
Free cash flow
—
Fetching…
Sources
Revenue
—
Net income
$-4.02M
Diluted EPS
-0.29
Operating cash flow
$-1.88M
Free cash flow
—
Fetching…
Sources
Revenue
—
Net income
$-4.45M
Diluted EPS
-0.40
Operating cash flow
$-5.50M
Free cash flow
—
Fetching…
Sources
Revenue
—
Net income
$-3.84M
Diluted EPS
-0.41
Operating cash flow
$-4.70M
Free cash flow
—
Fetching…
Sources
Revenue
—
Net income
$-2.31M
Diluted EPS
-0.26
Operating cash flow
$1.20M
Free cash flow
—
Fetching…
Sources
Is it cheap or expensive?
Fair value — vs current price $1.01
We couldn't calculate a fair value right now.
Is it drowning in debt?
Healthy
Net cash $11.3M - more cash than debt. Interest coverage -20.9x.
Net debt
$-11.33M
Interest coverage
-20.93x
Marker Therapeutics, Inc.'s profit covers its interest bill about 0.0 times over. which is weaker than most peers shown here and 4 peers sit below 1x, which is the danger zone where profit does not fully cover the interest bill.
Healthy
Worse cushion
Baseline
Better cushion
MRKR
BASELINE
Marker Therapeutics, Inc.
Total debt $0.00 Interest coverage -20.93x This is the baseline the peer rows are being compared against.
Total debt $596.00K Interest coverage -2,524.96x Neither company has much profit cushion over interest right now.
Total debt $1.40M Interest coverage -31.98x Neither company has much profit cushion over interest right now.
Total debt $0.00 Interest coverage -17.93x Neither company has much profit cushion over interest right now.
Total debt $28.74M Interest coverage -61.11x Neither company has much profit cushion over interest right now.
What you should know
The case for and against MRKR
0 Rewards
2 Risks
Rewards
Risks
-
Return on equity was -76.9% last year — the company lost money on shareholders' equity.
-
Insider ownership is only 5.5% (peer median: 8.8%).
The numbers
All the key metrics, grouped by purpose
Tap any ? icon to learn what it means.
Valuation
How expensive the stock looks
P/E (TTM)
—
Forward P/E
-1.91x
P/B
1.38x
P/S
4.75x
EV/EBITDA
—
PEG ratio
—
Profitability
How much profit each dollar creates
Gross margin
-148.3%
Operating margin
-268.0%
Net margin
-245.5%
ROE
-76.9%
ROA
-40.5%
Health
Liquidity and balance-sheet strength
Debt / equity
—
Current ratio
6.03x
Quick ratio
5.35x
Total debt
$0.00
Total cash
$11.33M
Growth
How the business has been compounding
Revenue TTM
$713.19K
Revenue 5Y CAGR
—
EPS TTM
-0.42
EPS 5Y CAGR
—
Cash flow
How much cash the business throws off
Operating CF TTM
$-9.76M
Free CF TTM
$-12.01M
FCF margin
-1,684.5%
Dividend
Shareholder payout
Yield
0.0%
Payout ratio
0.0%
Last ex-div date
—